Makers of anticancer drugs are “profiteering,” say 100 specialists from around the worldBMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f2810 (Published 30 April 2013) Cite this as: BMJ 2013;346:f2810
- Jeremy Laurance
- 1The Independent
More than 100 specialists in chronic myeloid leukaemia from around the world, including nine from the United Kingdom, have warned that the high prices that drug companies charge for anticancer drugs are leaving patients without access to treatments that could save their lives.
The group said that the drug industry was guilty of “profiteering” and compared its actions to those of unethical speculators who raise the price of grain after a natural disaster.
“What determines a morally justifiable ‘just price’ for a cancer drug?” they asked in a paper published in Blood.1 “A reasonable drug …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial